Calcineurin inhibitors (CNIs) are effective agents used for prevention of graft-vs-host disease after allogeneic hematopoietic stem cell transplant or for organ rejection in solid-organ transplant. However, CNIs have a wide range of adverse effects that may necessitate changing to another CNI or immunosuppressive agent. We report a case of acute myeloid leukemia in which achalasia developed after exposure to tacrolimus, as revealed by esophagram results. The patient's symptoms and signs were ameliorated after a change to cyclosporine. This case is the first in the literature to reveal achalasia associated with tacrolimus. Achalasia should be part of a differential diagnosis of upper gastrointestinal symptoms in patients undergoing transplant, and changing to another CNI may be a useful therapeutic intervention. 
C alcineurin inhibitors (CNIs) are commonly used for prophylaxis of graft-vs-host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) and for rejection in solid-organ transplant. 1 They are known to be associated with many adverse effects, including nephrotoxicity, hypertension, vulnerability to infection, and neurotoxicity. 2, 3 The gastrointestinal adverse effects of CNIs are mostly limited to nausea, vomiting, decreased oral intake, and elevation of liver enzyme levels. We present a compelling case of symptomatic achalasia likely induced by tacrolimus after allogeneic HSCT.
REPORT OF CASE
A 57-year-old male patient from Pakistan, with a history of acute promyelocytic leukemia and subsequent treatment-related acute myelocytic leukemia, received a reducedintensity, 10 out of 10 human leukocyte antigenematched, unrelated donor transplant. Conditioning pretransplant included administration of fludarabine and cyclophosphamide. For GVHD prophylaxis, tacrolimus and sirolimus were both started on day e3, with goal levels of 5 to 10 ng/mL for tacrolimus and 3-12 ng/ml for sirolimus; 5 mg/m 2 intravenous (IV) methotrexate was given on days þ1, þ3, þ6, and þ11 posttransplant. In addition, the patient was taking ursodiol, acyclovir, fluconazole, ceftriaxone, tamsulosin, and metoprolol. On day e1 from transplant, the patient reported odynophagia, which at the time was attributed to mucositis. Given that the patient's amylase and lipase levels were elevated (amylase peak value, 185 U/L; lipase, 223 U/L) and a computed tomography scan of the abdomen revealed mild stranding around the pancreas suspicious for pancreatitis, bowel rest, IV hydration, and pain medications were initiated. By day þ15, he had resumed oral intake but started experiencing worsening dysphagia with pills and solid food. Results of an oropharyngeal barium swallow test on day þ19 were normal, except for mildly reduced motility of the proximal esophagus. By day þ22, he was discharged home, although most of his medications were changed to liquid formulations, owing to persistent dysphagia.
On day þ33, the patient was readmitted to the hospital for IV antibiotic treatment of an 
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198 abscess on his right arm that was related to a peripherally inserted central catheter line. While the patient was in the hospital, he complained of dysphagia and retrosternal discomfort. A barium swallow test, this time assessing the entire esophagus, was obtained on day þ35 (Figure, A) . Results revealed persistent, marked, smooth narrowing of the lower esophageal sphincter, with substantially delayed emptying of liquid barium, in a manner consistent with achalasia. After administration of twice-daily pantoprazole, the patient's chest and abdominal pain improved. He began to tolerate pills and small quantities of food and was discharged from the hospital.
His improvement in oral intake was shortlived, and by day þ50, his dysphagia once again worsened. To evaluate for GVHD vs pseudoachalasia, the patient underwent endoscopy on day þ77. Results revealed mild duodenitis, but pathology test results were negative for GVHD and cytomegalovirus (CMV). Esophageal manometry results on day þ78 were consistent with achalasia, with The patient also began to experience severe generalized bone and muscle pain, which was suspected of being secondary to tacrolimus. In an effort to relieve his pain, on day þ84, tacrolimus was changed to cyclosporine. On day þ96, the patient underwent another outpatient esophagram, results of which were consistent with those of the previous one, except that they revealed more tertiary peristalsis (Figure, B) . At a follow-up visit on day þ140, the esophagram was repeated, and this time results revealed a much better esophageal motility pattern, with only minimally delayed emptying, and rapid progression of contrast into the esophagus (Figure, C) . However, the patient continued to complain of dysphagia, reflux, and upper abdominal pain. His appetite was poor because of these difficulties, and his weight was 64.5 kg (a 19% decrease from his pretransplant weight). Options for treatment of the achalasia were considered, including Heller myotomy, onabotulinum toxin A injection, and endoscopic balloon dilation. Given that less than 6 months had passed since the HSCT, invasive surgery was undesirable because of infection and wound-healing risks. A repeated endoscopy with onabotulinum toxin A injection was planned, owing to his ongoing weight loss and gastrointestinal symptoms.
At the patient's 6-month visit, he presented for his preeonabotulinum toxin A assessment and, surprisingly, reported marked improvement in his symptoms, with increased ability to eat solids and liquids. A repeated esophagram was obtained (Figure, D) . Results revealed a complete absence of lower esophageal sphincter narrowing, with peristaltically coordinated, normal prompt passage of contrast materials from the distal esophagus into the stomach and only minor dysmotility, as evidenced by only minimal and transient tertiary peristalsis. The patient reported corresponding improvement in his symptoms, and onabotulinum toxin A therapy was cancelled. A review of his history revealed that the only recent intervention or medication change was switching from tacrolimus to cyclosporine 3 months before the dramatic improvement in his esophageal motility.
DISCUSSION
To our knowledge, this case report is the first to discuss a new diagnosis of achalasia after allogeneic HSCT. Given the temporal relationship of development of an exacerbation of achalasia soon after starting tacrolimus and complete resolution after stopping, we suspect that starting tacrolimus was the most likely inciting cause. Koch et al 4 reported on a liver transplant recipient who experienced achalasia 3 months after transplant and for whom cyclosporine was started for organ rejection prophylaxis. When cyclosporine was changed to tacrolimus, the patient's esophageal mobility returned to normal. The authors speculated that this result may have occurred via inhibition of nitric oxide synthase (NOS) by CNIs.
Nitric oxide (NO) is present at the neurons along the entire esophageal lining, including the lower esophageal sphincter, and is not only responsible for appropriate relaxation of the sphincter to allow passage of food and liquid but also contributes to peristaltic movements of the body. Nitric oxide is synthesized by NOS. The inhibitory nonadrenergic noncholinergic neurons at the esophagus secrete NO (using their NOS) as a neurotransmitter, 5 causing hyperpolarization of the innervated muscle, inhibiting its contraction. If this mechanism is somehow disrupted, the unopposed activity of the activator neurons secreting acetylcholine may prevent proper relaxation, causing a stiff lower esophageal sphincter and a body with unsynchronized peristalsis. Several reports suggest that CNIs may decrease NO levels in other diseases, including hypertension, 6 inflammatory bowel disease, 7 and renal diseases. 8 Observations in the current case very likely result from decreased NO levels in the postganglionic neurons of the esophageal tract, leading to unopposed contractile activity. Changing from one drug to another was associated with resolution of achalasia within 3 months, in both our patient and the case reported by Koch et al. 4 Owing to the difference in chemical structure between tacrolimus and cyclosporine, various drugs within the same class may have widely varying effects in different patients. 
